



NEWS RELEASE

CRINETICS PHARMACEUTICALS TO PARTICIPATE IN THREE UPCOMING DECEMBER INVESTOR CONFERENCES

2024-11-15

SAN DIEGO – November 15, 2024 – **Crinetics Pharmaceuticals, Inc.** (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in three upcoming investment bank conferences. The Piper Sandler 36th Annual Healthcare Conference is being held in New York, NY, and both the Citi Global Healthcare Conference and the Evercore 7th Annual HealthCONx Conference are taking place in Miami, FL.

Evercore 7th Annual HealthCONx Conference

Fireside chat on Tuesday, December 3, 2024 at 7:30 a.m. Eastern Time

Webcast link [HERE](#)

Citi Global Healthcare Conference

Fireside chat on Wednesday, December 4, 2024 at 9:30 a.m. Eastern Time

Webcast link [HERE](#)

Piper Sandler 36th Annual Healthcare Conference

Fireside chat on Thursday, December 5, 2024 at 1:00 p.m. Eastern Time

Webcast link [HERE](#)

The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the



Crinetics' website at www.crinetics.com/events.

If you are interested in arranging a 1×1 meeting with management, please contact your conference representative.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. All of the company's drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:

Gayathri Diwakar

Head of Investor Relations

gdiwakar@crinetics.com

(858) 345-6340

Media:

Natalie Badillo

Head of Corporate Communications

nbadillo@crinetics.com

(858) 345-6075

Source: Crinetics Pharmaceuticals, Inc.